ReviewJournal of clinical and experimental hematopathology : JCEH2025
Prognostic and immunomodulatory roles of CD30 in diffuse large B-cell lymphoma: a cell-of-origin- and microenvironment-dependent paradigm.
Review in Journal of clinical and experimental hematopathology : JCEH, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The expression of CD30 in diffuse large B-cell lymphoma (DLBCL) has long been debated regarding its clinical significance. This report synthesizes the conflicting findings on CD30 and proposes a new paradigm. Central to this concept is that the prognostic value and biological function of CD30 are critically dependent on the lymphoma cell-of-origin (COO) and tumor microenvironment (TME) it shapes. Analysis of large-scale public gene expression datasets revealed that high CD30 expression is an independent favorable prognostic factor in DLBCL, but this effect is exclusively confined to the germinal center B-cell-like subtype. In contrast, CD30 expression showed no prognostic significance in the activated B-cell-like subtype. This specificity is attributable to CD30's role as a key architect of the TME, inducing an immune-tolerant environment, particularly through CD4+ T-cell infiltration and recruitment of regulatory T-cells. This understanding provides a strong rationale for COO- and TME-guided therapeutic strategies, such as combining the anti-CD30 antibody-drug conjugate brentuximab vedotin with immunomodulatory agents. This report elucidates the enigma of CD30 and outlines a path towards personalized medicine for DLBCL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.